论文期刊

取消

高级检索

检索历史清除

首页> Diabetologia: Clinical and Experimental Diabetes and Metabolism = Organ of the European Association for the Study of Diabetes (EASD)> Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

导出原文传递

翻译打印收藏纠错

作者： Nauck, Michael A. ^[1] ; Stewart, Murray W. ^[2] ; Perkins, Christopher ^[3] ; Jones-Leone, Angela ^[4] ; Yang, Fred ; Perry, Caroline ; Reinhardt, Rickey R. ; Rendell, Marc

作者单位： Creighton Univ, Omaha, NE 68178 USA ^[1] PPD Inc, Morrisville, NC USA ^[2] GlaxoSmithKline, King Of Prussia, PA USA ^[3] Ruhr Univ Bochum, St Josef Hosp, Gudrunstr 56, D-44791 Bochum, Germany ^[4]

关键词 Albiglutide GLP-1 agonist Randomised controlled trial Type 2 diabetes

发布时间 2017-04-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Diabetologia: Clinical and Experimental Diabetes and Metabolism = Organ of the European Association for the Study of Diabetes (EASD)

Diabetologia

2016年59卷2期

266-274页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

Diabetologia: Clinical and Experimental Diabetes and Metabolism = Organ of the European Association for the Study of Diabetes (EASD)

点击下载本期目录封面

Diabetologia

2016年59卷2期

266-274页

相关期刊

特别提示：本网站仅提供医学学术资源服务，不销售任何药品和器械，有关药品和器械的销售信息，请查阅其他网站。

客服热线：4000-115-888 转3 (周一至周五：8:00至17:00)
|
客服邮箱：yiyao@wanfangdata.com.cn

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

官方微信

万方医学小程序

关于我们网站地图知识产权

北京万方数据股份有限公司

万方数据电子出版社

京ICP证010071号

京公网安备11010802020237号

京ICP备08100800号-1

违法和不良信息举报电话：4000-115-888，举报邮箱：problem@wanfangdata.com.cn，举报专区

new翻译充值订阅收藏移动端

官方微信

万方医学小程序

调查问卷